Note : Comparison in this space is not easy due to high volatility in earnings growth especially during Covid and may not present accurate picture of earnings growth and valuation. PE ratio may optically look lower for some and higher for others unless adjusted for long term margins. Pharma companies across the board saw significant profit boost in FY22.